Venture Life Group plc (LON:VLG – Get Free Report) insider Paul McGreevy purchased 93,887 shares of the stock in a transaction dated Tuesday, June 30th. The shares were purchased at an average cost of GBX 64 per share, for a total transaction of £60,087.68.
Paul McGreevy also recently made the following trade(s):
- On Wednesday, June 3rd, Paul McGreevy acquired 15,663 shares of Venture Life Group stock. The shares were purchased at an average price of GBX 64 per share, with a total value of £10,024.32.
- On Wednesday, June 3rd, Paul McGreevy bought 48,373 shares of Venture Life Group stock. The stock was purchased at an average cost of GBX 62 per share, for a total transaction of £29,991.26.
- On Wednesday, June 3rd, Paul McGreevy bought 8,066 shares of Venture Life Group stock. The stock was purchased at an average cost of GBX 62 per share, for a total transaction of £5,000.92.
- On Wednesday, June 3rd, Paul McGreevy purchased 8,105 shares of Venture Life Group stock. The shares were purchased at an average price of GBX 62 per share, with a total value of £5,025.10.
Venture Life Group Stock Performance
Shares of LON VLG traded up GBX 0.50 during midday trading on Tuesday, hitting GBX 67. 509,774 shares of the company’s stock traded hands, compared to its average volume of 303,704. The firm has a fifty day moving average of GBX 61.27 and a 200 day moving average of GBX 64.91. Venture Life Group plc has a 1 year low of GBX 52 and a 1 year high of GBX 72. The company has a debt-to-equity ratio of 0.82, a quick ratio of 1.48 and a current ratio of 4.71. The stock has a market capitalization of £81.62 million, a price-to-earnings ratio of 15.33, a price-to-earnings-growth ratio of 5.67 and a beta of 0.23.
About Venture Life Group
Venture Life is an international consumer self-care company focused on developing and commercialising products for the global self-care market helping our consumers live a longer healthier and more rewarding life.
Headquartered in the UK, the Group’s product portfolio includes Balance Activ in the area of women’s intimate healthcare, Earol® supporting ENT care, Lift and Glucogel product ranges for energy and glucose management and hypoglycaemia, plus the Health & Her product range supporting the hormonal lifecycle.
The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through health & beauty stores, pharmacies, grocery multiples and e-commerce channels and are sold globally.
Featured Stories
- Five stocks we like better than Venture Life Group
- Why Wall Street Still Sees Massive Upside for AeroVironment Stock
- Why AppLovin’s CEO Is Selling While Quantum Insiders Are Buying
- Volkswagen’s 16-Year Low Masks a Massive Margin Engine
- Palantir’s Rough 2026 Start Raises a Bigger Question About Its AI Moat
Receive News & Ratings for Venture Life Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Venture Life Group and related companies with MarketBeat.com's FREE daily email newsletter.
